Uniqure (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
Other equities analysts also recently issued reports about the company. BidaskClub upgraded Uniqure from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Janney Montgomery Scott started coverage on Uniqure in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 target price for the company. HC Wainwright set a $35.00 target price on Uniqure and gave the company a “buy” rating in a research report on Thursday, March 15th. Finally, ValuEngine upgraded Uniqure from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $21.38.
Uniqure (NASDAQ:QURE) last posted its earnings results on Wednesday, March 14th. The biotechnology company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.23). The firm had revenue of $2.58 million during the quarter, compared to the consensus estimate of $2.83 million. Uniqure had a negative net margin of 604.72% and a negative return on equity of 174.25%. research analysts anticipate that Uniqure will post -3.21 EPS for the current year.
In other news, insider Deventer Sander Van sold 5,985 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $18.53, for a total value of $110,902.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Schaffer sold 2,878 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $18.53, for a total value of $53,329.34. Following the completion of the sale, the director now directly owns 15,314 shares of the company’s stock, valued at approximately $283,768.42. The disclosure for this sale can be found here. In the last three months, insiders sold 48,032 shares of company stock valued at $1,014,982. Insiders own 0.73% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in shares of Uniqure in the fourth quarter valued at about $119,000. Perceptive Advisors LLC increased its stake in shares of Uniqure by 0.8% in the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock valued at $20,529,000 after buying an additional 7,831 shares during the period. Ellington Management Group LLC acquired a new stake in shares of Uniqure in the fourth quarter valued at about $237,000. Goldman Sachs Group Inc. acquired a new stake in shares of Uniqure in the fourth quarter valued at about $373,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Uniqure in the fourth quarter valued at about $389,000. 42.76% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3337638/uniqure-qure-stock-rating-upgraded-by-zacks-investment-research.html.
Uniqure Company Profile
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.